Dudediligence.

Fate Therapeutics, Inc

FATENASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$361,786

7 notices · 191,490 sh

Oct 2025 to Oct 2026

Reported ·

$119,305

4 sales · 0 buys

Oct 2025 to Jun 2026

The two figures cover different periods.

None of the 4 reported sales carry the 10b5-1 box. Together they are 0.06% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-08-04: TAHL CINDY, Form 1442026-08-04: Valamehr Bahram, Form 1442026-05-20: Valamehr Bahram, Form 1442026-05-20: TAHL CINDY, Form 1442026-01-09: TAHL CINDY, Form 1442026-01-09: Valamehr Bahram, Form 1442025-12-24: MENDLEIN JOHN, Form 1442026-01-09: Valamehr Bahram, sold2026-01-09: TAHL CINDY, sold2026-05-20: Valamehr Bahram, sold2026-05-20: TAHL CINDY, sold
under a no plan named▼ salesize is dollars

Form 144 notices, newest first

2026-08-04TAHL CINDY, See Remarks$95,405
38,800 shno plan dateForm 4s on file end Jun 23144 ↗
2026-08-04Valamehr Bahram, President and CEO$108,101
43,947 shno plan dateForm 4s on file end Jun 23144 ↗
2026-05-20Valamehr Bahram, President and CEO$54,482
28,946 shno plan date144 ↗
Form 4, 2026-05-21: sold 28,946 at $1.88 Form 4 ↗
2026-05-20TAHL CINDY, See Remarks$48,084
25,590 shno plan date144 ↗
Form 4, 2026-05-21: sold 25,590 at $1.88 Form 4 ↗
2026-01-09TAHL CINDY, See Remarks$11,275
10,589 shno plan date144 ↗
Form 4, 2026-01-12: sold 10,589 at $1.06 Form 4 ↗
2026-01-09Valamehr Bahram, President and CEO$5,557
5,190 shno plan date144 ↗
Form 4, 2026-01-12: sold 5,190 at $1.07 Form 4 ↗
2025-12-24MENDLEIN JOHN, Former Director$38,881
38,428 shno plan dateno Form 4 on file144 ↗